MedTrace Logo

Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorder

NCT03494738 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-09-02

No results posted yet for this study

Summary

The objective of the study is to validate epigenetic changes as biomarkers in a prospective sampling of newborn blood samples collected at birth (umbilical cord blood) and during routine screening (heel stick blood) in newborns concurrently tested for alcohol exposure levels by PEth blood spot testing.

Conditions

  • Fetal Alcohol Spectrum Disorders

Sponsors & Collaborators

  • United States Drug Testing Laboratories, Inc.

    collaborator UNKNOWN

  • CAMC Health System

    lead OTHER

Principal Investigators

  • Stefan Maxwell, MD · CAMC Women and Children's Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-12
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03494738 on ClinicalTrials.gov